Article Details

Xeris Biopharma Eyes High End Of FY21 Sales Outlook - Benzinga

Retrieved on: 2022-01-18 15:41:41

Tags for this article:

Click the tags to see associated articles and topics

Xeris Biopharma Eyes High End Of FY21 Sales Outlook - Benzinga. View article details on hiswai:

Excerpt

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has.

Article found on: m.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up